PAKAR Laboratories LTD (Ghana) A Medicinal Fermentation Company

Our innovation is based on using large scale medicinal fermentation to produce highly active compounds libraries from fungi. To prospect for anti-cancer compounds we employ the unique differences between two yeast strains, Candida albicans and Saccharomyces cerevisiae and in their selective sensitivities to compounds. Putative anti-cancer compounds are deemed to those that are only selective active against Saccharomyces cerevisiae. On this basis we have discovered 65 hits that putative anti-cancer compounds ready for a hit-to-lead validation study and scale up production. Those that are selectively active against Candida albicans and also active against both strains have scored as bonafide antifungal compounds. We think that the 65 putative anti-cancer compounds offer us the opportunity to advance towards developing useful anticancer drugs especially liver cancer, one of the most refractory cancers to chemotherapies. In additional to the 65 hits, we discovered 9 slow-acting compounds.